Global Point-of-Care (POC) Drug Abuse Testing Market, By Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others) - Industry Trends and Forecast to 2031.
Point-of-Care (POC) Drug Abuse Testing Market Analysis and Size
The market is driven by increasing awareness and emphasis on drug abuse prevention and management, along with the growing need for quick and accurate drug testing in diverse environments. Key factors fueling market growth include rising drug abuse rates, stringent regulatory requirements for drug testing in workplaces, and advancements in POC testing technologies that offer enhanced accuracy and user convenience. Additionally, the growing prevalence of substance abuse disorders across different demographics contributes to the demand for effective and accessible drug testing solutions.
The global Point-of-Care (POC) drug abuse testing market encompasses a range of diagnostic technologies and solutions designed to detect the presence of illicit substances or controlled drugs in an individual’s system at the location of care, rather than in a traditional laboratory setting. These tests provide rapid, on-the-spot results, which are crucial for timely decision-making and intervention in various settings such as medical facilities, emergency rooms, workplaces, and even in home settings. The market includes devices and testing kits for detecting drugs in urine, saliva, blood, and other biological samples.
Data Bridge Market Research analyzes that the global Point-of-Care (POC) drug abuse testing market is expected to reach USD 2.01 billion by 2031 from USD 1.41 billion in 2023, growing with a CAGR of 4.7% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Drug Type (Amphetamines, Opiates, Cannabinoids, Cocaine, Barbiturates, Benzodiazepines, Methadone, Phencyclidine, Tricyclic Antidepressants, and Others), Products (Devices and Consumables and Accessories), Prescription (Over the Counter Testing and Prescription-Based Testing), Sample Type (Urine, Saliva, Blood, Hair, Breath, and Others), Testing Type (Random Testing, Post-Incident Testing, and Abstinence Testing), Application (Medical Screening, Workplace Screening, Law Enforcement and Criminal Justice, Pain Management, Substance Abuse Treatment and Rehabilitation, Parental or Home Drug Testing, Sports and Athletics Testing, Drug Screening in Schools and Educational Institutions, and Others), End User (Healthcare Facilities, Employers, Government Institutes, and Others), Distribution Channel (Direct Tender, Retails Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Norway, Austria, Hungary, Ireland, Kazakhstan, Belarus, Lithuania, Uzbekistan, Azerbaijan, Armenia, Moldova, Tajikistan, Kyrgyzstan, Poland, Rest of Europe, Brazil, Argentina, Colombia, Peru, Chile, EI Salvador, Panama, Bolivia, Costa Rica, Ecuador, Guatemala, Paraguay, Venezuela, Dominican Republic, Cuba, Uruguay, Rest of Latin America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Kuwait, and Rest of Middle East and Africa, China, India, Japan, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and Rest of Asia-Pacific
|
|
Market Players Covered
|
Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., F.Hoffman-La Roche Ltd., Siemens Healthineers AG, MP Biomedicals., Beijing Hotgen Biotechn Co., LTD., Assure Tech (Hangzhou) co., ltd., Accubio Tech Co., ltd. Premier biotech,inc., and Wondfo, among others
|
Market Definition
Point-of-Care (PoC) drug abuse testing refers to rapid screening methods used to detect the presence of drugs or their metabolites in a person's system at the site of care, such as clinics or emergency rooms. These tests provide quick results, enabling timely decision-making for treatment or intervention. Typically involving urine, saliva, or blood samples, PoC testing is essential for monitoring substance use, ensuring patient safety, and facilitating access to appropriate support services.
Global Point-of-Care (POC) Drug Abuse Testing Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:
Drivers
- Rising Incidence of Drug Abuse
Drug abuse involving opiates, cannabinoids, and amphetamines has been growing globally, creating a public health crisis that requires immediate and scalable solutions. Healthcare providers, law enforcement agencies, and employers are increasingly relying on POC drug testing as it offers rapid, accurate, and on-site detection, which is critical in managing the consequences of drug abuse.
In healthcare, the need for quick detection of drug abuse is essential to offer timely interventions, especially in emergency cases or rehabilitation centers. In law enforcement, the ability to test individuals on-site accelerates decision-making and enhances efforts to curb drug-related crimes. Similarly, workplaces are adopting POC drug testing to maintain a drug-free environment, reduce liability, and comply with safety regulations.
Technological advancements in POC testing devices further support the growing demand for rapid, reliable testing methods. These devices are becoming more portable, user-friendly, and capable of detecting a wide range of substances, making them ideal for use in non-laboratory settings.
For instance,
- In January 2024, according to an article published by NCBI, Opioid Use Disorder (OUD) affects over 16 million people worldwide, including 2.1 million in the U.S., leading to more than 120,000 deaths globally each year. The prevalence of opioid use and dependency is high, with up to 50% of long-term opioid users meeting OUD criteria. The rising incidence of opioid-related issues drives the need for effective drug testing solutions, thereby fuelling growth in the global Point-of-Care (POC) drug abuse testing market
Growth in Home and Parental Drug Testing Kits
The growing demand for easy-to-use, over-the-counter drug testing kits for home use reflects a strong consumer preference for privacy and convenience in monitoring substance use. Parents are increasingly adopting these kits to detect and prevent substance abuse among teenagers, while individuals are opting for self-testing options for personal reasons.
Technological advancements have led to the creation of more accurate, reliable, and user-friendly drug testing products, enabling consumers to perform tests privately at home without professional assistance. This convenience reduces the stigma associated with drug testing, fostering wider adoption of these solutions. Home testing kits are now more sensitive and capable of detecting a broad range of drugs, providing results that are comparable to those from laboratory tests.
Opportunity
- Growing Awareness and the Campaign for Drug Testing
The increasing awareness surrounding the dangers of drug abuse, coupled with robust public health campaigns and government support, presents a significant opportunity for growth in the global Point-of-Care (POC) drug abuse testing market. As society becomes more cognizant of the detrimental impacts of substance abuse, there is a growing demand for accessible and effective testing solutions. Public health campaigns, often spearheaded by governmental and non-governmental organizations, play a crucial role in educating communities about the importance of early detection and intervention. These initiatives not only amplify the visibility of drug abuse issues but also advocate for the use of point-of-care testing as a preventive measure. Furthermore, government support through funding and policy-making enhances the accessibility of POC drug testing solutions by promoting regulatory frameworks that facilitate the adoption of these technologies in various settings, including workplaces, schools, and public health programs. The combination of heightened awareness and strategic support fosters an environment conducive to market expansion, driving innovation and increasing the availability of advanced testing solutions to address the evolving needs of society.
Hence, the convergence of growing awareness, active public health campaigns, and strong government support is poised to significantly benefit the global Point-of-Care (POC) drug abuse testing market. This dynamic environment not only promotes the adoption of drug testing technologies but also encourages the development of more sophisticated and accessible solutions. As these factors continue, the future of POC drug abuse testing looks promising, with enhanced opportunities for innovation, broader market reach, and improved public health outcomes.
Restraint/Challenge
- High Costs Associated with the Testing
The complexity of developing reliable and accurate POC drug abuse tests often requires advanced technology, specialized materials, and rigorous validation processes, all of which contribute to elevated production costs. These costs are further compounded by stringent regulatory requirements, as ensuring compliance with international standards demands extensive testing, quality control, and documentation, adding to the overall expense. Additionally, the need for consistent research and development to keep pace with emerging drug abuse patterns and to enhance the sensitivity and specificity of these tests drives up the costs even more. For healthcare providers, the high upfront investment required to integrate these testing solutions into their practices can be prohibitive, particularly for smaller clinics or organizations with limited budgets. This financial burden can deter the adoption of POC drug abuse testing despite its potential benefits in terms of speed and convenience. The situation is exacerbated in low- and middle-income countries, where healthcare budgets are already strained, and the added cost of POC testing can be a barrier to implementation, limiting the market's expansion into these regions. Moreover, the high cost can lead to disparities in healthcare access, as only well-funded institutions may be able to afford these advanced testing methods, leaving vulnerable populations without adequate testing and care. This challenge is not only a financial one but also an ethical issue, as the inability to provide affordable testing solutions undermines the efforts to combat drug abuse on a broader scale.
Recent Developments
- In August 2024, Abbott announced a global partnership with Medtronic on August 7, 2024, to integrate Abbott's advanced FreeStyle Libre Continuous Glucose Monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aimed to enable automatic insulin adjustments and improve diabetes management, benefiting over 11 million people worldwide. Financial terms were undisclosed
- In March 2024, Abbott extended its partnership with Real Madrid and the Real Madrid Foundation through the 2026-2027 season, continuing as their global health sciences and nutrition partner. Since 2021, Abbott provided over 25,000 hours of nutrition education and screened more than 3,000 children for malnutrition
- In August 2023, SSM Health, Siemens Healthineers partner to advance health equity and empower workforce development in underserved communities. The partnership with SSM Health benefits Siemens Healthineers by expanding its market presence, increasing visibility of its technology, fostering long-term growth, and enhancing its reputation in the healthcare sector
- In February 2024, Roche entered into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics. The collaboration provides Roche with PathAI’s advanced AI technology for improving companion diagnostics. It ensures exclusive, tailored solutions and accelerates algorithm development while allowing Roche to continue developing its own diagnostics
- In November 2023, Roche launched next-generation qPCR system to advance clinical needs in molecular diagnostics and address public health challenges. Roche’s next-generation qPCR system boosts its market position, meets clinical and public health needs, and opens new revenue opportunities while showcasing its commitment to innovation
Global Point-of-Care (POC) drug abuse testing market Scope
The global Point-of-Care (POC) drug abuse testing market is segmented into eight notable segments based on drug type, products, prescription, sample type, testing type, application, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Drug Type
- Amphetamines
- Opiates
- Cannabinoids
- Cocaine
- Barbiturates
- Benzodiazepines
- Methadone
- Phencyclidine
- Tricyclic Antidepressants
- Others
On the basis of drug type, the market is segmented into amphetamines, cannabinoids, opiates, cocaine, benzodiazepines, barbiturates, phencyclidine, methadone, tricyclic antidepressants, and others.
Products
- Devices
- Consumables and Accessories
On the basis of products, the market is segmented into devices and consumables and accessories.
Prescription
- Over the Counter Testing
- Prescription-Based Testing
On the basis of prescription mode, the market is segmented into prescription-based testing, and over the counter testing.
Sample Type
- Urine
- Saliva
- Blood
- Hair
- Breath
- Others
On the basis of sample type, the market is segmented into urine, saliva, blood, hair, breath, and others.
Testing Type
- Random Testing
- Post-Incident Testing
- Abstinence Testing
On the basis of testing type, the market is segmented into random testing, post-incident testing, and abstinence testing.
Application
- Medical Screening
- Workplace Screening
- Law Enforcement and Criminal Justice
- Pain Management
- Substance Abuse Treatment and Rehabilitation
- Parental or Home Drug Testing
- Sports and Athletics Testing
- Drug Screening in Schools and Educational Institutions
- Others
On the basis of application, the market is segmented medical screening, workplace screening, law enforcement and criminal justice, pain management, substance abuse treatment and rehabilitation, parental or home drug testing, sports and athletics testing, drug screening in schools and educational institutions, and others.
End User
- Healthcare Facilities
- Employers
- Government Institutes
- Others
On the basis of end user, the market is segmented into healthcare facilities, employers, government institute, and others.
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retails sales, and others.
Global Point-of-Care (POC) Drug Abuse Testing Market Regional Analysis/Insights
Global Point-of-Care (POC) drug abuse testing market is analyzed, and market size insights and trends are provided by based on drug type, products, prescription, sample type, testing type, application, end user, distribution channel as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Norway, Austria, Hungary, Ireland, Kazakhstan, Belarus, Lithuania, Uzbekistan, Azerbaijan, Armenia, Moldova, Tajikistan, Kyrgyzstan, Poland, rest of Europe, Brazil, Argentina, Colombia, Peru, Chile, EI Salvador, Panama, Bolivia, Costa Rica, Ecuador, Guatemala, Paraguay, Venezuela, Dominican Republic, Cuba, Uruguay, rest of Latin America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, Kuwait, and rest of Middle East and Africa, China, India, Japan, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, and rest of Asia-Pacific.
North America is expected to dominate the market due to factors like high prevalence of cold sores, advanced healthcare infrastructure, strong consumer awareness and purchasing power, ongoing research and development initiatives, established marketing and distribution networks, and reduced stigma surrounding treatment-seeking behaviors. The U.S. is expected to dominate in the North America market due to factors such as high healthcare expenditure, sophisticated healthcare system, and extensive pharmaceutical industry, Germany is expected to dominate in the Europe market due to its advanced healthcare infrastructure, significant consumer demand for cold sore treatments, strong pharmaceutical industry, extensive research and development efforts, and well-established distribution networks, making it a hub for innovation and accessibility in cold sore management. China is expected to dominate in the Asia-Pacific market due to its large population and coupled with a developing healthcare infrastructure and a rising prevalence of cold sores.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Point-of-Care (POC) Drug Abuse Testing Market Share Analysis
The global Point-of-Care (POC) drug abuse testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the global Point-of-Care (POC) drug abuse testing market.
Some of the major players operating in the global Point-of-Care (POC) drug abuse testing market are Abbott Laboratories, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., F.Hoffman-La Roche Ltd., Siemens Healthineers AG, MP Biomedicals., Beijing Hotgen Biotechn Co., LTD., Assure Tech (Hangzhou) co., ltd., Accubio Tech Co., ltd. Premier biotech,inc., and Wondfo, among others.
SKU-